NCT04028388 2024-04-17ModraDoc006/r vs Docetaxel IV in Metastatic Prostate CancerModra PharmaceuticalsPhase 2 Completed135 enrolled 29 charts
NCT03575819 2024-02-01A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Fortis Therapeutics, Inc.Phase 1 Completed56 enrolled
NCT03646162 2021-12-03Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate CancerVeru Inc.Phase 2 Completed93 enrolled 18 charts
NCT02407054 2021-05-11A Study of Enzalutamide and LY3023414 in Men With Prostate CancerEli Lilly and CompanyPhase 2 Completed142 enrolled 16 charts
NCT02074137 2016-06-02Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate CancerSanofiPhase 4 Completed10 enrolled
NCT01254279 2015-01-21Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenSanofiPhase 3 Completed984 enrolled
NCT01595087 2014-11-14A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)DexTech Medical ABPhase 1/2 Completed28 enrolled